AGA Medical Buy-Out Likely In Wake Of Legal, Regulatory Headaches
This article was originally published in The Gray Sheet
Executive Summary
Private equity investor Welsh, Carson, Anderson & Stowe is understood to be backing AGA Medical co-founder Franck Gougeon's bid to purchase the remaining half of the Amplatzer manufacturer
You may also be interested in...
Supporting Japan Applications With U.S. Data Is Slower, But Worth It – AGA
AGA Medical will support its second regulatory application in Japan with U.S. data - despite the Japanese health ministry's preference for domestic data - because Japanese trials are prohibitively expensive, according to CEO Franck Gougeon
AGA Medical litigation
Amplatzer manufacturer announces a resolution of litigation between its two shareholders, July 29. Under the agreement, Franck Gougeon assumes CEO and majority shareholder roles. Former HHS Secretary Tommy Thompson will be board chairman and inventor Kurt Amplatz returns to the firm as a board member. Private equity investor Welsh, Carson, Anderson & Stowe - which formerly backed Gougeon's bid to purchase the remaining half of AGA - has taken a "significant" ownership position (1"The Gray Sheet" May 9, 2005, p. 7). Although it is operating under an FDA application integrity policy, AGA says it will continue its RESPECT clinical trial of its patent foramen ovale occlusion device for prevention of recurrent strokes...
AGA Medical litigation
Amplatzer manufacturer announces a resolution of litigation between its two shareholders, July 29. Under the agreement, Franck Gougeon assumes CEO and majority shareholder roles. Former HHS Secretary Tommy Thompson will be board chairman and inventor Kurt Amplatz returns to the firm as a board member. Private equity investor Welsh, Carson, Anderson & Stowe - which formerly backed Gougeon's bid to purchase the remaining half of AGA - has taken a "significant" ownership position (1"The Gray Sheet" May 9, 2005, p. 7). Although it is operating under an FDA application integrity policy, AGA says it will continue its RESPECT clinical trial of its patent foramen ovale occlusion device for prevention of recurrent strokes...